314 related articles for article (PubMed ID: 33581097)
1. Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).
Vizza CD; Hoeper MM; Huscher D; Pittrow D; Benjamin N; Olsson KM; Ghofrani HA; Held M; Klose H; Lange T; Rosenkranz S; Dumitrescu D; Badagliacca R; Claussen M; Halank M; Vonk-Noordegraaf A; Skowasch D; Ewert R; Gibbs JSR; Delcroix M; Skride A; Coghlan G; Ulrich S; Opitz C; Kaemmerer H; Distler O; Grünig E
Chest; 2021 Aug; 160(2):678-689. PubMed ID: 33581097
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias.
Hoeper MM; Behr J; Held M; Grunig E; Vizza CD; Vonk-Noordegraaf A; Lange TJ; Claussen M; Grohé C; Klose H; Olsson KM; Zelniker T; Neurohr C; Distler O; Wirtz H; Opitz C; Huscher D; Pittrow D; Gibbs JS
PLoS One; 2015; 10(12):e0141911. PubMed ID: 26630396
[TBL] [Abstract][Full Text] [Related]
3. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).
Olsson KM; Delcroix M; Ghofrani HA; Tiede H; Huscher D; Speich R; Grünig E; Staehler G; Rosenkranz S; Halank M; Held M; Lange TJ; Behr J; Klose H; Claussen M; Ewert R; Opitz CF; Vizza CD; Scelsi L; Vonk-Noordegraaf A; Kaemmerer H; Gibbs JS; Coghlan G; Pepke-Zaba J; Schulz U; Gorenflo M; Pittrow D; Hoeper MM
Circulation; 2014 Jan; 129(1):57-65. PubMed ID: 24081973
[TBL] [Abstract][Full Text] [Related]
4. Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis.
Hoeper MM; Dwivedi K; Pausch C; Lewis RA; Olsson KM; Huscher D; Pittrow D; Grünig E; Staehler G; Vizza CD; Gall H; Distler O; Opitz C; Gibbs JSR; Delcroix M; Park DH; Ghofrani HA; Ewert R; Kaemmerer H; Kabitz HJ; Skowasch D; Behr J; Milger K; Lange TJ; Wilkens H; Seyfarth HJ; Held M; Dumitrescu D; Tsangaris I; Vonk-Noordegraaf A; Ulrich S; Klose H; Claussen M; Eisenmann S; Schmidt KH; Swift AJ; Thompson AAR; Elliot CA; Rosenkranz S; Condliffe R; Kiely DG; Halank M
Lancet Respir Med; 2022 Oct; 10(10):937-948. PubMed ID: 35777416
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary Arterial Hypertension-Specific Drug Therapy in COPD Patients with Severe Pulmonary Hypertension and Mild-to-Moderate Airflow Limitation.
Calcaianu G; Canuet M; Schuller A; Enache I; Chaouat A; Kessler R
Respiration; 2016; 91(1):9-17. PubMed ID: 26492415
[TBL] [Abstract][Full Text] [Related]
6. Long-term effect of vasodilator therapy in pulmonary hypertension due to COPD: a retrospective analysis.
Fossati L; Müller-Mottet S; Hasler E; Speich R; Bloch KE; Huber LC; Ulrich Somaini S
Lung; 2014 Dec; 192(6):987-95. PubMed ID: 25348430
[TBL] [Abstract][Full Text] [Related]
7. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis.
Poms AD; Turner M; Farber HW; Meltzer LA; McGoon MD
Chest; 2013 Jul; 144(1):169-176. PubMed ID: 23348820
[TBL] [Abstract][Full Text] [Related]
8. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
[TBL] [Abstract][Full Text] [Related]
9. Diffusing Capacity Is an Independent Predictor of Outcomes in Pulmonary Hypertension Associated With COPD.
Balasubramanian A; Kolb TM; Damico RL; Hassoun PM; McCormack MC; Mathai SC
Chest; 2020 Aug; 158(2):722-734. PubMed ID: 32184109
[TBL] [Abstract][Full Text] [Related]
10. [Pulmonary arterial hypertension in patients with congenital heart disease: current issues and health care situation].
Kaemmerer H; Gorenflo M; Hoeper M; Huscher D; Ewert P; Pittrow D
Dtsch Med Wochenschr; 2013 Jun; 138(23):1247-52. PubMed ID: 23720182
[TBL] [Abstract][Full Text] [Related]
11. Udenafil improves exercise capacity in patients with chronic obstructive pulmonary disease: a prospective study.
Park JS; Lim HJ; Cho YJ; Lee JH; Yoon HI; Lee CT
COPD; 2012 Aug; 9(5):499-504. PubMed ID: 22946546
[TBL] [Abstract][Full Text] [Related]
12. Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results.
Nathan SD; Argula R; Trivieri MG; Aziz S; Gay E; Medarov B; Parambil J; Raina A; Risbano MG; Thenappan T; Soto JS; Bell H; Lacasse V; Sista P; Di Marino M; Smart A; Hawkes B; Nelson E; Bull T; Tapson V; Waxman A
Eur Respir J; 2024 Jun; 63(6):. PubMed ID: 38811045
[TBL] [Abstract][Full Text] [Related]
13. Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension.
Wang L; Jin YZ; Zhao QH; Jiang R; Wu WH; Gong SG; He J; Liu JM; Jing ZC
Int J Chron Obstruct Pulmon Dis; 2017; 12():3353-3360. PubMed ID: 29200842
[TBL] [Abstract][Full Text] [Related]
14. Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum.
Opitz CF; Hoeper MM; Gibbs JS; Kaemmerer H; Pepke-Zaba J; Coghlan JG; Scelsi L; D'Alto M; Olsson KM; Ulrich S; Scholtz W; Schulz U; Grünig E; Vizza CD; Staehler G; Bruch L; Huscher D; Pittrow D; Rosenkranz S
J Am Coll Cardiol; 2016 Jul; 68(4):368-78. PubMed ID: 27443433
[TBL] [Abstract][Full Text] [Related]
15. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.
Hoeper MM; Simonneau G; Corris PA; Ghofrani HA; Klinger JR; Langleben D; Naeije R; Jansa P; Rosenkranz S; Scelsi L; Grünig E; Vizza CD; Chang M; Colorado P; Meier C; Busse D; Benza RL
Eur Respir J; 2017 Sep; 50(3):. PubMed ID: 28889107
[TBL] [Abstract][Full Text] [Related]
16. Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis.
Degano B; Sitbon O; Savale L; Garcia G; O'Callaghan DS; Jaïs X; Humbert M; Simonneau G
Chest; 2010 Jun; 137(6):1297-303. PubMed ID: 20118205
[TBL] [Abstract][Full Text] [Related]
17. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
[TBL] [Abstract][Full Text] [Related]
18. Portopulmonary hypertension: a report from the US-based REVEAL Registry.
Krowka MJ; Miller DP; Barst RJ; Taichman D; Dweik RA; Badesch DB; McGoon MD
Chest; 2012 Apr; 141(4):906-915. PubMed ID: 21778257
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis.
Frost AE; Badesch DB; Miller DP; Benza RL; Meltzer LA; McGoon MD
Chest; 2013 Nov; 144(5):1521-1529. PubMed ID: 23907471
[TBL] [Abstract][Full Text] [Related]
20. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.
Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost A; Engel P; Kramer MR; Serdarevic-Pehar M; Layton GR; Sitbon O; Badesch DB;
J Heart Lung Transplant; 2014 Jul; 33(7):689-97. PubMed ID: 24815795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
